Journal of Korean Society for Clinical Pharmacology and Therapeutics  2013;21(2):95-103

doi:10.12793/jkscpt.2013.21.2.95

Comparison of Pharmacokinetic Characteristics and Safety Between JW Amlodipine(R) Tablet 5 mg and Novarsc(R) Tablet 5 mg in Healthy Male Volunteers.

Yo Han KIM 1 ; Hyeong Seok LIM ; Sang Heon CHO ; Jong Lyul GHIM ; Sangmin CHOE ; Jin Ah JUNG ; Kyun Seop BAE

Affiliations

+expand

Keywords

Amlodipine; Pharmacokinetics; Safety; Healthy volunteers

Country

Republic of Korea

Language

Korean

Abstract

BACKGROUND: Amlodipine is a third-generation dihydropyridine calcium channel blocker, which has proven to be a useful drug against hypertension or angina. METHODS: This randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in twenty healthy male volunteers. Subjects were administered 5 mg of the test or reference formulation. After 2-week washout period, the other formulation was administered. Blood samples were collected up to 144 hours after drug administration, and plasma amlodipine concentrations were determined by validated liquid chromatography-tandem mass spectrometry. Drug safety was assessed using measurement of vital signs, physical examinations, laboratory test, electrocardiograms, and adverse event monitoring. RESULTS: All subjects were completed this study. The geometric mean ratios of Cmax and AUClast were 1.078 (90 % CI, 0.968 - 1.200) and 1.095 (90 % CI, 1.011 - 1.186), respectively. There were no serious adverse events were reported by both formulations. CONCLUSION: This study showed the test and reference formulations had similar pharmacokinetics and safety profiles.